Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Four American families are facing a daunting challenge as they strive to secure funding for their children suffering from an agonizing genetic disease. The cure is within reach, but they must raise an astounding $1.15 million to initiate a clinical trial.
Each of these families has a child diagnosed with spastic paraplegia 50 (SPG50), a rare neurological disorder that impacts fewer than 100 people globally. The urgency of their situation underscores the critical need for immediate action and awareness in the medical community.
In an emotional interview with Fox News Digital, the families shared their harrowing race against time to acquire the necessary treatment. The clock is ticking, and every moment counts.
To facilitate their fundraising efforts, the families established a nonprofit organization called Jack’s Corner, aiming to streamline the process and draw attention to their plight. Their goal is to raise the required funds by the end of October to commence the trial in the United States.
What is SPG50?
SPG50 impedes a child’s development, progressively leading to cognitive impairment, muscle weakness, speech delays, and eventually paralysis. According to the National Organization for Rare Disorders, the prognosis varies significantly among affected individuals, but it is generally a progressive condition.
Dr. Eve Elizabeth Penney, an epidemiologist at the Texas Department of State Health Services, elaborated on the disorder’s progression. Children with SPG50 may encounter early developmental delays, muscle weakness, and spasticity. As their condition advances, they can struggle with basic activities like walking and daily living tasks.
Currently, there is no treatment for SPG50 approved by the U.S. Food and Drug Administration (FDA). However, a potential solution exists, thanks to Terry Pirovolakis, a Canadian father determined to save his son who was diagnosed in 2017.
A Father’s Fight for a Cure
Pirovolakis recounted the moment doctors gave him devastating news about his son. They advised him to go home and cherish their remaining time together, predicting that his son would be paralyzed from the waist down by age ten and quadriplegic by age twenty. This prognosis was intolerable for Pirovolakis, who refused to accept defeat.
Driven by love and determination, he set out to find a solution. He liquidated his savings, consulted numerous specialists, and financed scientists to develop a gene therapy. In March 2022, his son received the therapy and has since made significant strides in his health. Following this success, Pirovolakis launched a Phase 2 study in the U.S., treating three more children, all of whom reported halting disease progression and witnessing cognitive improvements.
The families now aspire to transition into a Phase 3 trial, enabling treatment for more children. However, since the drug lacks FDA approval, the burden falls on the families to raise the necessary funds.
Desperation and Hope
Rebekah Lockard from Littleton, Colorado, is among those desperate to secure treatment for her four-year-old daughter, Naomi. Naomi was diagnosed with SPG50 in 2023. In contrast, Lockard’s younger son, Jack, received the therapy in a previous trial. This has led to a noticeable difference between the siblings.
“Naomi is unable to walk and relies on a wheelchair, while Jack is making progress with a walker,” Lockard explained. “Every day, we are grateful for Jack’s treatment, but we feel despair knowing we haven’t been able to provide Naomi with the same opportunities.”
Emma and Dylan Jobsis from Juneau, Arkansas, also shared their plight regarding their son Cade, who was diagnosed in 2023. Emma expressed her fear about Cade potentially losing the ability to walk without treatment. This daily worry grips the family as they seek funding for a trial that could change everything for their son.
Jordan and Cody Medeiros from Scio, Oregon, are similarly devastated. Their four-year-old son, Lincoln, has been steadily losing his ability to walk since his SPG50 diagnosis two years ago. This reality is challenging, particularly since they know that eight doses of the necessary treatment are currently waiting to be administered.
Meanwhile, in Susquehanna, Pennsylvania, Jami and Cody Wood celebrated the birth of twins in 2022. However, their joy turned to despair when they learned that one of their daughters, Mila, had SPG50 just weeks later. Despite the grim prognosis, Mila recently took her first steps, an achievement that her parents view as bittersweet.
Seeking FDA Approval
The families hope that a successful Phase 3 trial will secure FDA approval for the drug, which would allow insurance companies and government agencies to alleviate the financial burden of treatment. Pirovolakis emphasized that achieving FDA approval is crucial for uprooting the disease and improving the lives of affected children.
He highlighted the importance of including SPG50 in the newborn screening panel, thereby enhancing the likelihood of early detection and intervention.
Pirovolakis and his team are in active conversations with the FDA, but the path to approval is anything but straightforward. Currently, the FDA applies the same stringent manufacturing standards to small studies like his as it does for larger diseases affecting a broader population. This poses a significant hurdle for families facing ultra-rare conditions like SPG50.
“We are in dire need of flexibility from the FDA,” Pirovolakis asserted. “The requirements can be overwhelming for conditions that impact so few children.”
A Call to Action
As these families rally to raise funds and awareness, their fight underscores a significant gap in resources available for rare diseases. They need support from communities, organizations, and individuals to create a path for the future treatment of SPG50.
By advocating for changes in the regulatory environment and raising funds for essential research, there is hope that these families will one day see their children live free from the shackles of this devastating disease.
The collective effort of these families shines a light on the desperate need for innovative solutions in the realm of rare genetic disorders. Every donation, every share, and every voice matters in the fight against SPG50.
